TRAIL及其受体与HBV相关慢性肝病相关性的研究进展

摘要

肿瘤坏死因子相关凋亡诱导配体（TNF-related apoptosis inducing ligand, TRAIL）归属于肿瘤坏死因子超家族，与死亡受体结合后，激活caspase瀑布样级联反应，可诱导肿瘤细胞、转化细胞及病毒感染细胞发生凋亡，而对正常组织及细胞无凋亡诱导作用。TRAIL及其受体通过与HBV、细胞因子等的相互作用，在HBV相关慢性肝病的发病机制中发挥着重要作用。此外，体内TRAIL表达还与慢性乙型病毒性肝炎患者抗病毒治疗存在一定的关联性。本文对TRAIL及其受体与HBV相关慢性肝病的相关性进行综述，为进一步明确两者间的关系提供理论依据。%Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) belongs to the tumor necrosis factor (TNF) superfamily. After TRAIL bound to death receptor, waterfall-like cascade reaction of caspase can be activated. Tumor cells, transformed cells and virus-infected cells can be induced to undergo apoptosis by this reaction, but it has not produce apoptosis function in normal tissues and cells. By interacting with hepatitis B virus (HBV), cytokines and other factors, TRAIL and its receptors play an important role in the pathogenesis of HBV-related chronic liver disease. In addition, it has a correlation between TRAIL expressionin vivo and chronic hepatitis B (CHB) patients with antiviral treatment. This review focuses on the correlation between TRAIL and its receptors and HBV-related chronic liver disease, and provides a theoretical basis for their relationship.